Actinium Pharmaceuticals, Inc. SEC filings ATNM
Actinium Pharmaceuticals, Inc. has 511 filings in SEC EDGAR's recent list, going back to Feb 5, 2007. Its latest annual report, Form ARS, was filed on Oct 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 15, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Oct 15, 2026 | Nov 25, 2026 |
| DEF 14A | Proxy statement | Nov 5, 2025 | Nov 26, 2025 |
| DEF 14A | Proxy statement | Nov 5, 2024 | Nov 27, 2024 |
| DEF 14A | Proxy statement | Nov 9, 2023 | Nov 30, 2023 |
| DEFA14A | Additional proxy material | Dec 9, 2022 | — |
| DEF 14A | Proxy statement | Nov 21, 2022 | Dec 8, 2022 |
| DEFA14A | Additional proxy material | Nov 5, 2021 | — |
| DEF 14A | Proxy statement | Oct 18, 2021 | Nov 9, 2021 |
| DEFA14A | Additional proxy material | Oct 28, 2020 | — |
| DEFA14A | Additional proxy material | Oct 7, 2020 | — |
| DEF 14A | Proxy statement | Oct 7, 2020 | Nov 18, 2020 |
| DEF 14A | Proxy statement | Nov 25, 2019 | Dec 18, 2019 |
| PRE 14A | Preliminary proxy statement | Nov 15, 2019 | Nov 15, 2019 |
| DEF 14A | Proxy statement | Nov 16, 2018 | Dec 18, 2018 |
| PRE 14A | Preliminary proxy statement | Oct 30, 2018 | Nov 8, 2018 |
| DEF 14A | Proxy statement | Nov 14, 2017 | Dec 20, 2017 |
| PRE 14A | Preliminary proxy statement | Oct 30, 2017 | Dec 20, 2017 |
| DEFA14A | Additional proxy material | Dec 14, 2016 | — |
| DEFA14A | Additional proxy material | Dec 8, 2016 | — |
| DEFA14A | Additional proxy material | Nov 30, 2016 | — |
| DEF 14A | Proxy statement | Nov 18, 2016 | Dec 21, 2016 |
| DEFA14A | Additional proxy material | Nov 27, 2015 | — |
| DEF 14A | Proxy statement | Nov 12, 2015 | Oct 16, 2015 |
| DEF 14A | Proxy statement | Nov 14, 2014 | Dec 22, 2014 |
| PRE 14A | Preliminary proxy statement | Nov 3, 2014 | Nov 3, 2014 |
| DEF 14A | Proxy statement | Nov 26, 2013 | Dec 2, 2013 |
| PRE 14A | Preliminary proxy statement | Nov 12, 2013 | Nov 11, 2013 |
| DEF 14C | Information statement | Jan 29, 2013 | Jan 28, 2013 |
| PRE 14C | Preliminary 14c information statement | Dec 17, 2012 | Dec 14, 2012 |
| DEF 14C | Information statement | Nov 13, 2007 | Nov 13, 2007 |
| PRE 14C | Cactus ventures, inc. preliminary information statement 11.2.07 | Nov 2, 2007 | Nov 2, 2007 |
Showing 31 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ATNM (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1388320
- Former names
- Cactus Ventures, Inc. (until Mar 29, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.